Kailera is advancing a broad and differentiated portfolio of clinical-stage injectable and oral GLP-1 therapies for obesity and related conditions.
Total raised: $400M
Investors 1
| Date | Name | Website |
| 04.10.2024 | Bain Capit... | baincapita... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 07.10.2024 | Series A | $400M | - |
Mentions in press and media 5
| Date | Title | Description |
| 01.11.2024 | The 10 Biggest Rounds Of October: OpenAI’s Massive Deal Dwarfs All Others | 2 Shares Email Facebook Twitter LinkedIn This is a monthly feature that runs down the month’s top 10 funding rounds in the U.S. Check out September’s biggest rounds here. OpenAI led the way last month and it really wasn’t even close. Howeve... |
| 07.10.2024 | Kailera Therapeutics: $400 Million (Series A) Raised To Advance Next-Gen Therapies For Obesity | Kailera Therapeutics announced its launch as a clinical-stage biopharmaceutical company focused on advancing a broad pipeline of next-generation therapies for treating obesity and related conditions. And Kailera launches with a $400 million... |
| 01.10.2024 | Kailera Therapeutics Launches with $400M in Series A Financing | Kailera Therapeutics, a Boston, MA-based clinical-stage biopharmaceutical company, launched with $400M in Series A funding. The round was led by Atlas Venture, Bain Capital Life Sciences, and RTW Investments, with participation from Lyra Ca... |
| 01.10.2024 | Kailera launches with $400M series A and clutch of Chinese obesity drugs | Kailera Therapeutics has launched into the increasingly crowded obesity space with a portfolio of assets acquired from China and $400 million in series A funds. The Massachusetts- and California-based biotech is led by former Cerevel Therap... |
| - | Kailera Therapeutics | “Kailera is advancing a broad and differentiated portfolio of clinical-stage injectable and oral GLP-1 therapies for obesity and related conditions.” |